28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
Patients with Alzheimer's disease have higher plasma homocysteine levels than controls, but it is uncertain whether higher plasma homocysteine levels are involved in the early pathogenesis of the disease. 1 key finding →
Participants: 511 Evidence: low
Full summary, score breakdown and related studies → Original source
Hippocampal T2 hyperintensity after FSE represents acute injury often evolving to a radiological appearance of HS after 1 year. 3 key findings →
Participants: 226 Evidence: low
Full summary, score breakdown and related studies → Original source
The role of structural brain magnetic resonance imaging (MRI) is becoming more and more emphasized in the early diagnostics of Alzheimer's disease (AD). 3 key findings →
Participants: 834 Evidence: low
Full summary, score breakdown and related studies → Original source
Exposure to maternal anxiety predicts offspring brain development. 1 key finding →
Participants: 175 Evidence: low
Full summary, score breakdown and related studies → Original source
PTSD in youth is common and debilitating. 1 key finding →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
Socioeconomic disparities-and particularly differences in educational attainment-are associated with remarkable differences in cognition and behavior across the life-span. 4 key findings →
Participants: 275 Evidence: low
Full summary, score breakdown and related studies → Original source
Shifting policies towards legalisation of cannabis for therapeutic and recreational use raise significant ethical issues for health-care providers seeking evidence-based recommendations. 4 key findings →
Participants: 111 Evidence: low
Full summary, score breakdown and related studies → Original source
Cerebral small-vessel disease is common in older people and may contribute to the development of dementia. 5 key findings →
Participants: 832 Evidence: low
Full summary, score breakdown and related studies → Original source
Memory declined more rapidly in AD patients with higher educational and occupational attainment. 5 key findings →
Participants: 177 Evidence: low
Full summary, score breakdown and related studies → Original source
Pathological studies have demonstrated abnormalities in white matter that may appear normal on brain imaging. 3 key findings →
Participants: 429 Evidence: low
Full summary, score breakdown and related studies → Original source
Enlarged perivascular spaces are associated with age, lacunar stroke subtype and white matter lesions and should be considered as another magnetic resonance imaging marker of cerebral small vessel disease. 3 key findings →
Participants: 298 Evidence: low
Full summary, score breakdown and related studies → Original source
Although internal factors explain most about the poor nutritional status of aged residents in nursing homes, the factors related to nutritional care need further investigation to clarify their role in maintaining the nutritional status of aged residents. 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Diabetic patients are at increased risk for stroke, but little is known about the presence of other brain lesions. 3 key findings →
Participants: 1,252 Evidence: low
Full summary, score breakdown and related studies → Original source
Low and high thyrotropin levels were associated with an increased risk of incident AD in women but not in men. 5 key findings →
Participants: 209 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) and vascular dementia (VaD) are the two most common forms of dementia. 1 key finding →
Participants: 800,000 Evidence: low
Full summary, score breakdown and related studies → Original source
This is the first study that focuses on insomnia in stroke patients. 5 key findings →
Participants: 277 Evidence: low
Full summary, score breakdown and related studies → Original source
This study identified the plasma biomarker analytes and assays that most accurately classified amyloid pathology and other AD-related outcomes. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
P-tau isoforms can be measured robustly by several novel high-sensitive Simoa assays. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Lower Aß-42 levels were associated with a reported decline in memory and language abilities, and with the following SCD-plus features: onset of subjective decline within 5 years, confirmation of cognitive decline by an informant, and decline-related worries. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
HIGHLIGHTS: Different plasma phosphorylated tau (p-tau) species reflect different pathological processes of Alzheimer's disease (AD), with p-tau231 showing the greatest association with the earliest increases in brain amyloid beta (Aβ) accumulation, while p-tau217 shows greater association with both brain Aβ and early tau pathology, and other p-tau and tau fragment species show greater association with later stages of brain tau pathology. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
WMH are only weakly and inconsistently associated with cognitive decline, which may be explained by heterogeneity of the underlying neuropathological substrates. 5 key findings →
Participants: 104 Evidence: low
Full summary, score breakdown and related studies → Original source
Neurofilament light chain (NfL) is a novel biomarker of neurodegenerative diseases. 3 key findings →
Participants: 43 Evidence: low
Full summary, score breakdown and related studies → Original source
The present patients with positive GFAP-immunoglobulin G are highly similar to autoimmune GFAP astrocytopathy, described in a recent report. 3 key findings →
Participants: 19 Evidence: low
Full summary, score breakdown and related studies → Original source
This mass spectrometry-based plasma biomarker test: has strong diagnostic performance; can accurately distinguish brain amyloid positive from amyloid negative individuals; may aid in the diagnostic evaluation process for Alzheimer's disease; and may enhance the efficiency of enrolling participants into Alzheimer's disease drug trials. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
In a population of cognitively unimpaired adults with increased risk of AD, long-term exposure to air pollution was associated with higher levels in biomarkers of AD pathology. 5 key findings →
Participants: 156 Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →